Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy

Trends in Pharmacological Sciences

Volumn 38, Issue 9, 2017, Pages 765-770

  Lauschke, Volker M ^a   Ivanov, Maxim ^b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ANALYTIC METHOD; EPIGENETIC REGULATION; EPIGENETIC SAMPLING; EPIGENETICS; EPIGENOMIC PROFILING; GENETIC ANALYSIS; GENETIC REGULATION; HUMAN; LIQUID BIOPSY; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; NONHUMAN; OXIDATIVE BISULFITE METHOD; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SAMPLING; TET ASSISTED BISULFITE BASED METHOD; ANIMAL; DIAGNOSTIC PROCEDURE; GENETIC EPIGENESIS; MOUSE; PROCEDURES;

ANIMALS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; MICE; PROGNOSIS;

EID: 85020736659     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.05.007     Document Type: Review

References (57)

1. Lauschke, V.M., Ingelman-Sundberg, M., The importance of patient-specific factors for hepatic drug response and toxicity. Int. J. Mol. Sci., 17, 2016, E1714.
2. Lauschke, V.M., et al. Pharmacoepigenetics and toxicoepigenetics: novel mechanistic insights and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol., 2017 (in press).
3. Michels, K.B., et al. Recommendations for the design and analysis of epigenome-wide association studies. Nat. Methods 10 (2013), 949–955.
4. Birney, E., et al. Epigenome-wide association studies and the interpretation of disease -omics. PLoS Genet., 12, 2016, e1006105.
5. Tahiliani, M., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (2009), 930–935.
6. Kriaucionis, S., Heintz, N., The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324 (2009), 929–930.
7. Ivanov, M., et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol., 14, 2013, R83.
8. Globisch, D., et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One, 5, 2010, e15367.
9. Kunderfranco, P., et al. DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy. Nat. Commun., 7, 2016, 12418.
10. Page, A., et al. Hepatic stellate cell transdifferentiation involves genome-wide remodeling of the DNA methylation landscape. J. Hepatol. 64 (2016), 661–673.
11. Barlow, D.P., Bartolomei, M.S., Genomic imprinting in mammals. Cold Spring Harb. Perspect. Biol., 6, 2014, a018382.
12. Fisel, P., et al. DNA methylation of ADME genes. Clin. Pharmacol. Ther. 99 (2016), 512–527.
13. Chen, W.-D., et al. Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver. Hepatology 56 (2012), 1499–1508.
14. El-Khoury, V., et al. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br. J. Cancer 97 (2007), 562–573.
15. Sharma, S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 (2010), 69–80.
16. Yong, W.-S., et al. Profiling genome-wide DNA methylation. Epigenetics Chromatin, 9, 2016, 26.
17. Huang, Y., et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One, 5, 2010, e8888.
18. Xu, Y., et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 42 (2011), 451–464.
19. Stroud, H., et al. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol., 12, 2011, R54.
20. Wen, L., et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol., 15, 2014, R49.
21. Matarese, F., et al. 5-Hydroxymethylcytosine: a new kid on the epigenetic block?. Mol. Syst. Biol., 7, 2011 562–562.
22. Yu, M., et al. Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. Nat. Protoc. 7 (2012), 2159–2170.
23. Booth, M.J., et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 336 (2012), 934–937.
24. Ivanov, M., et al. Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. Nucleic Acids Res. 44 (2016), 6756–6769.
25. Kawasaki, Y., et al. A novel method for the simultaneous identification of methylcytosine and hydroxymethylcytosine at a single base resolution. Nucleic Acids Res., 45, 2017, e24.
26. Amouroux, R., et al. De novo DNA methylation drives 5hmC accumulation in mouse zygotes. Nat. Cell Biol. 18 (2016), 225–233.
27. Chen, H.-Y., et al. Spectroscopic quantification of 5-hydroxymethylcytosine in genomic DNA using boric acid-functionalized nano-microsphere fluorescent probes. Biosens. Bioelectron. 91 (2017), 328–333.
28. Sims, D., et al. Sequencing depth and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15 (2014), 121–132.
29. Ziller, M.J., et al. Coverage recommendations for methylation analysis by whole-genome bisulfite sequencing. Nat. Methods 12 (2015), 230–232 1 p. following 232.
30. Park, P.J., ChIP-seq: advantages and challenges of a maturing technology. Nat. Rev. Genet. 10 (2009), 669–680.
31. Kim, M.-S., et al. Common errors in mass spectrometry-based analysis of post-translational modifications. Proteomics 16 (2016), 700–714.
32. Nakato, R., Shirahige, K., Recent advances in ChIP-seq analysis: from quality management to whole-genome annotation. Brief. Bioinform. 18 (2017), 279–290.
33. Sadikovic, B., et al. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr. Genomics 9 (2008), 394–408.
34. Yu, H., et al. Inferring causal relationships among different histone modifications and gene expression. Genome Res. 18 (2008), 1314–1324.
35. Gravina, S., et al. Single-cell genome-wide bisulfite sequencing uncovers extensive heterogeneity in the mouse liver methylome. Genome Biol., 17, 2016, 150.
36. Hannon, E., et al. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics 10 (2015), 1024–1032.
37. Bonder, M., et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics, 15, 2014 860–813.
38. Lunnon, K., et al. Variation in 5-hydroxymethylcytosine across human cortex and cerebellum. Genome Biol., 17, 2016, 27.
39. Tiili, E.M., et al. Effect of genotype and methylation of CYP2D6 on smoking behaviour. Pharmacogenet. Genomics 25 (2015), 531–540.
40. Somineni, H.K., et al. Ten-eleven translocation 1 (TET1) methylation is associated with childhood asthma and traffic-related air pollution. J. Allergy Clin. Immunol., 137, 2016 797–805.e5.
41. Swartz, J.R., et al. An epigenetic mechanism links socioeconomic status to changes in depression-related brain function in high-risk adolescents. Mol. Psychiatry 22:2 (2017), 209–214.
42. Shimada-Sugimoto, M., et al. Epigenome-wide association study of DNA methylation in panic disorder. Clin. Epigenetics, 9, 2017, 6.
43. Moran, S., et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 17 (2016), 1386–1395.
44. Bram, E.E., et al. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11 (2009), 1359–1370.
45. Fisel, P., et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin. Cancer Res. 19 (2013), 5170–5181.
46. Snyder, M.W., et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164 (2016), 57–68.
47. Lehmann-Werman, R., et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E1826–E1834.
48. Guo, S., et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49 (2017), 635–642.
49. Lian, C.G., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150 (2012), 1135–1146.
50. Yang, H., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32 (2012), 663–669.
51. Abolhoda, A., et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5 (1999), 3352–3356.
52. Tada, Y., et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin. Cancer Res. 6 (2000), 4618–4627.
53. Bram, E.E., et al. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11 (2009), 1359–1370.
54. Liu, Y., et al. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci. Transl. Med., 8, 2016, 348ra97.
55. Knoechel, B., et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 46 (2014), 364–370.
56. Coronel, J., et al. A double-blind, placebo-controlled, randomized Phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med. Oncol. 28:Suppl. 1 (2010), S540–S546.
57. San-Miguel, J.F., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind Phase 3 trial. Lancet Oncol. 15 (2014), 1195–1206.